Your browser doesn't support javascript.
loading
Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives.
Tisi, Dominic; Chiarparin, Elisabetta; Tamanini, Emiliano; Pathuri, Puja; Coyle, Joseph E; Hold, Adam; Holding, Finn P; Amin, Nader; Martin, Agnes C L; Rich, Sharna J; Berdini, Valerio; Yon, Jeff; Acklam, Paul; Burke, Rosemary; Drouin, Ludovic; Harmer, Jenny E; Jeganathan, Fiona; van Montfort, Rob L M; Newbatt, Yvette; Tortorici, Marcello; Westlake, Maura; Wood, Amy; Hoelder, Swen; Heightman, Tom D.
Afiliação
  • Tisi D; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Chiarparin E; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Tamanini E; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Pathuri P; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Coyle JE; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Hold A; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Holding FP; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Amin N; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Martin AC; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Rich SJ; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Berdini V; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Yon J; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
  • Acklam P; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Burke R; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Drouin L; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Harmer JE; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Jeganathan F; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • van Montfort RL; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Newbatt Y; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Tortorici M; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Westlake M; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Wood A; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Hoelder S; CRUK Cancer Therapeutics Unit, Institute of Cancer Research , 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG.
  • Heightman TD; Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0QA.
ACS Chem Biol ; 11(11): 3093-3105, 2016 11 18.
Article em En | MEDLINE | ID: mdl-27571355
ABSTRACT
The members of the NSD subfamily of lysine methyl transferases are compelling oncology targets due to the recent characterization of gain-of-function mutations and translocations in several hematological cancers. To date, these proteins have proven intractable to small molecule inhibition. Here, we present initial efforts to identify inhibitors of MMSET (aka NSD2 or WHSC1) using solution phase and crystal structural methods. On the basis of 2D NMR experiments comparing NSD1 and MMSET structural mobility, we designed an MMSET construct with five point mutations in the N-terminal helix of its SET domain for crystallization experiments and elucidated the structure of the mutant MMSET SET domain at 2.1 Å resolution. Both NSD1 and MMSET crystal systems proved resistant to soaking or cocrystallography with inhibitors. However, use of the close homologue SETD2 as a structural surrogate supported the design and characterization of N-alkyl sinefungin derivatives, which showed low micromolar inhibition against both SETD2 and MMSET.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Oncogenes / Proteínas Repressoras / Adenosina / Histona-Lisina N-Metiltransferase / Epigênese Genética Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Oncogenes / Proteínas Repressoras / Adenosina / Histona-Lisina N-Metiltransferase / Epigênese Genética Idioma: En Ano de publicação: 2016 Tipo de documento: Article